ArticleBiochemical and biophysical research communications1997
The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells.
Article in Biochemical and biophysical research communications, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 91 citations in OpenAlex.
- Spinal AJournal of neuroscience research · 2022Article
- Neonatal Seizures and Purinergic Signalling.International journal of molecular sciences · 2020Review
- Article
- AExperimental brain research · 2018Article
- Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.British journal of pharmacology · 2016Review
- Pain and Poppies: The Good, the Bad, and the Ugly of Opioid Analgesics.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Review
- Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy.Brain, behavior, and immunity · 2015Article
- Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.Brain : a journal of neurology · 2015Article
- Purinergic signalling and cancer.Purinergic signalling · 2013Review
- Glial adenosine kinase--a neuropathological marker of the epileptic brain.Neurochemistry international · 2013Review
- Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.Journal of medicinal chemistry · 2013Article
- Controlling murine and rat chronic pain through A3 adenosine receptor activation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy.Epilepsia · 2012Article
- A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.The American journal of pathology · 2011Article
- Adenosine receptors and cancer.Handbook of experimental pharmacology · 2009Review
- The Anti-Cancer Effect of AImmunology, endocrine & metabolic agents in medicinal chemistry · 2007Article
- Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃ adenosine receptor.Purinergic signalling · 2006Article
- Role of direct RhoA-phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2004Article
- A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.Molecular pharmacology · 2002Article
- p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA.Biochemical pharmacology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
The pathophysiological role of the adenosine A3 receptor in the central nervous system is largely unknown. We have investigated the effects of the selective A3 receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine, Cl-IB-MECA, in cells of the astroglial lineage (human astrocytoma ADF cells). A marked reorganization of the cytoskeleton, with appearance of stress fibers and numerous cell protrusions, was found following exposure of cells to low (nM) concentrations of Cl-IB-MECA. These "trophic" effects were accompanied by induction of the expression of Rho, a small GTP-binding protein, which was virtually absent in control cells, and by changes of the intracellular distribution of the antiapoptotic protein Bcl-XL, that, in agonist-exposed cells, became specifically associated to cell protrusions. This is the first demonstration that the intracellular organization of Bcl-XL can be modulated by the activation of a G-protein-coupled membrane receptor, such as the A3 adenosine receptor. Moreover, modulation of the astrocytic cytoskeleton by adenosine may have intriguing implications in both nervous system development and in the response of the brain to trauma and ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.